The Institut du Cancer Courlancy First to Install Advanced ZAP-X Gyroscopic Radiosurgery Platform in Europe

ZAP Surgical Systems announced that the Institut du Cancer Courlancy (ICC) in Reims, France will add ZAP-X® Gyroscopic Radiosurgery® platform, the latest advancement in non-invasive brain tumor treatments.

In a collaboration between the radiation oncology and neurosurgery teams, the site looks to solidify their status as a regional oncology center-of-excellence by dedicating ZAP-X to the treatment of cranial-based indications, thereby complementing the institute’s existing modern fleet of radiation delivery systems optimized for the treatment of lung, breast, prostate, and other cancers of the body.

Radiosurgery, also referred to as SRS, is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors. For eligible indications, SRS is a completely non-invasive and pain-free alternative to expensive and often debilitating surgeries.

ZAP-X system relies on the latest surgical robotic technology and novel gyroscopic mobility to concentrate high-intensity radiation on tumor targets while minimizing incidental radiation exposure to normal brain tissue and nearby healthy organs.

The ZAP-X system is the first new dedicated cranial radiosurgery platform in nearly half a century. Prior to ZAP-X, state-of-the-art SRS often required hospitals to manage large quantities of expensive and volatile Cobalt-60 for radiosurgery beam generation. ZAP-X eliminates this historical requirement by using leading-edge linear accelerator technology, and thus removes the burdens of perpetual source decay and costs of recurring isotope replacement.